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Background: Although current guidelines do not recommend immediate anticoagulation therapy (IAC) for acute ischemic 
stroke, judicious debates are still lingering on whether it might be done for acute cardioembolic stroke (ACES). We surveyed 
current practice patterns of anticoagulation therapy for ACES in Korea, and analyzed their related factors. Methods: Using a 
web-based system, all neurology staffs of training hospitals in Korea surveyed about when and how they commenced antico-
agulation therapy in the hypothetical cases with ACES. Results: Of the 359 subjects invited, 281 responded to the e-mail, of 
whom 76 abstained from participating. The number of participants was therefore 205 (57.1%). Although a few physicians (4.4%) 
always performed IAC and some (10.7%) never did, most physicians made different decisions according to infarct size and 
presence of hemorrhagic transformation (HTr): IAC was performed more often in cases with medium-sized or small infarct than 
large one (68.2% vs. 35.9%, P<0.001), and in cases without HTr (68.6% vs. 34.9%, P<0.001). The most common method of 
administration was ‘heparin followed by warfarin’ (68.2%), and then ‘warfarin alone’ or ‘warfarin with aspirin’. If IAC was not 
commenced, it resumed most commonly between 1 and 2 weeks after the onset (44.0%). Conclusion: Quite many neurologists 
in Korea did IAC in selective ACES, e.g. small sized infarction without HTr. Further studies are needed to prove the effi cacy of 
IAC therapy in this selective population. (Korean J Stroke 2011;13:120-128)
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Introduction
The annual risk of stroke is approximately 4.5% in patients 
with atrial fibrillation (AF).1 This climbs to 12% in patients 
with AF and a previous history of stroke.2 Many randomized 
controlled studies have clearly established that long-term oral 
anticoagulation can reduce the risk of stroke by about 65%.3
However, anticoagulation therapy (AC) is generally not 
recommended in acute cardioembolic stroke (ACES), despite 
the apparent benefi ts of long-term AC.4 This is due to concern 
about the risk of hemorrhagic transformation (HTr). In previous 
studies with patients with ACES, early AC was shown to give no 
advantage in terms of long-term functional outcome, due to the 
benefi ts from stroke prevention being cancelled out by the in-
creased risk of HTr.5,6 HTr can result in unfavourable functional 
outcome, and is more common in patients with ACES than in 
patients with other stroke types.7 
Despite these previous discouraging results, however, in 
clinical practice many physicians seem to favour immediate 
anticoagulation therapy (IAC) in ACES patients with small 
infarct. More research in this area is needed due to the lack of 
practice guidelines in the appropriate time and method for the 
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commencement of AC. In this study, we conducted a survey of 
current AC practice in ACES. We also elicited factors related to 
the AC practice in the acute phase. 
Methods
Study design and subjects
We surveyed 359 teaching hospital staff faculties (including 
instructors and professors) registered with the Korean Neuro-
logical Association as of May 2010, using a web-based online 
survey system. 
E-mails were sent to all subjects, explaining the aims of the 
survey and requesting participation. When the recipients of the 
e-mail clicked on the button to participate in the survey, it was 
linked to the survey website so that they could respond to the 
survey. The survey results from the website were sent online to 
the investigators. If a recipient clicked on the button to decline 
survey participation, they could select a reason for declining 
before ending the survey: 1) not in charge of any acute stroke 
cases, 2) not interested in the topic, 3) others. The options chosen 
as the reasons for declining were also sent online to the inves-
tigators. We encouraged recipients who did not respond to the 
e-mail by sending two additional e-mails at 4 day intervals.
 
Survey Structure and Content
Preliminary questions 
The list of survey participants was generated from the Korean 
Neurological Association database. Prior to the AC questions, 
the respondents were asked the following preliminary questions: 
1) whether the participant was a stroke specialist (or whether 
stroke is a major field of interest); 2) the average number of 
monthly admitted acute stroke patients, 3) whether their hospital 
had a stroke unit.
Contents of Survey
The survey was structured for participants to select the treat-
ment methods they would use in hypothetical cases.We first 
involving a half or more of middle cerebral artery territory with no hemorrhagic transformation. (B) Case 2. Medium-sized infarct 
involving 1/2 to 1/3 of middle cerebral artery territory with no hemorrhagic transformation. (C) Case 3. Medium-sized infarct involving 
1/2 to 1/3 of middle cerebral artery territory with no hemorrhagic transformation. (D) Case 4. Small infarct involving less than one 
third of middle cerebral artery territory with no hemorrhagic transformation. (E) Case 5. Small infarct involving less than one third of 
middle cerebral artery territory ith mild hemorrhagic transformation. (F) Case 6. Lare cerebellar infarct involving whole or near whole 
territory of posterior infererior cerebellar artery with no hemorrhagic transformation. (G) Case 7. Small cerebellar infarct involving 
less than whole or near whole territory of posterior infererior cerebellar artery with no hemorrhagic transformation.
FIGURE 1. Seven hypothetical acute cardioembolic stroke 
cases with atrial fibrillation were presented in 24 hours of 
symptom onset. We described the infarct location and size on 
diffusion weighted imaging and the presence of hemorrhagic 
transformation (hemorrhagic infarction, no parenchymal 
hematoma) on gradient echo imaging. (A) Case 1. Large infarct
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described the seven hypothetical cases of ACES with AF accord-
ing to the infarct location and size as seen on diffusion weighted 
imaging (DWI) in 24 hours of onset, and the presence of HTr 
(hemorrhagic infarction, no parenchymal hematoma) seen on 
gradient echo imaging (GRE) (Figure 1): Case 1) Large supra-
tentorial infarct (>1/2 middle cerebral artery (MCA) territory) 
without HTr, Case 2) Medium sized supratentorial infarct (1/2-1/3 
MCA territory) without HTr, Case 3) Medium sized supratento-
rial infarct with HTr, Case 4) Small supratentorial infarct (<1/3 
MCA territory) without HTr, Case 5) Small supratentorial infarct 
with HTr, Case 6) Large cerebellar infarct (entire/nearly entire 
posterior inferior cerebellar artery (PICA) territory) without HTr, 
Case 7) Small cerebellar infarct (<PICA territory) without HTr. 
In each case, we asked whether they would commence IAC. If 
they did commence IAC, they chose the method of AC from 
the following: 1) heparin bridging (warfarin after administration 
of dose adjusted intravenous unfractionated heparin or low-
molecular-weight heparin (LMWH)), 2) aspirin bridging (war-
farin with aspirin), 3) warfarin alone. If they did not commence 
IAC (delayed anticoagulation, DAC), they chose the time of AC 
commencement from the following: 1) within 1 week of symp-
tom onset, 2) between 1 and 2 weeks after onset, 3) >2 weeks 
after onset. Next, regarding one case with a past history of spon-
taneous intracerebral hemorrhage (ICH, Case 8), and one with 
multiple cerebral microbleeds (CMBs) detected on GRE (Case 
9), we asked participants to select the following options on AC: 
1) usually no AC, 2) usually AC regardless, 3) not applicable 
because no AC for any acute patients. The original questionnaire 
is presented in Appendix 1.
Analysis of survey results
For each case, we performed a descriptive analysis of the 
responses. We then analysed factors related to decisions to com-
mence IAC, method of IAC administration, and commencement 
time in cases of DAC, by combining participants’ responses for 
all cases. Parameters analysed were participant age, whether 
the participant was a stroke specialist, number of acute stroke 
patients, presence of a dedicated stroke unit, large infarct, HTr, 
and the infarct site. Age and the number of acute stroke patients 
were stratifi ed as above and below the median value, and above 
and below 30 monthly patients, respectively. The infarct site was 
classified as supratentorial and cerebellar infarcts. Univariate 
analysis was performed using the chi-square test. We performed 
logistic regression analysis including all variables above for 
determination of independent factors related to the decision 
whether to start IAC. A P value of <0.05 was interpreted as sta-
tistically signifi cant. 
Results
Survey response rate and participant characteristics
Of the 359 subjects invited to participate, 281 (78.3%) 
responded to the e-mail, of whom 76 stated that they did not 
wish to participate. The number of participants was therefore 
205 out of 359 (57.1%). For the reason for non-participation, 54 
respondents (71.1%) selected 1) not in charge of any acute stroke 
cases, 11 (14.5%) selected 2) not interested in the study, 5 (5.0%) 
selected 3) others, and 6 (6.0%) did not specify. 
The mean age of the 205 survey participants was 43.3±5.7 
years, with 103 participants above the age of 43. Stroke was the 
specialty for 139 participants (67.8%). The number of monthly 
admissions for acute stroke exceeded 30 for 131 (63.9%) partici-
pants, and 103 (50.2%) stated that their hospital had a dedicated 
stroke unit.
Treatment methods for each case
The reported treatment method for each case is shown in detail 
in Table 1. For a large supratentorial or large cerebellar infarct 
without HTr (Cases 1 & 6), most participants chose DAC (64.4% 
and 63.9%, respectively), and many of them chose to commence 
AC between 1-2 weeks after onset (53.0%, 46.6%). On the other 
hand, for small or medium size infarcts without HTr (Cases 2, 
4, & 7), most participants chose IAC (86.6-93.2%). However, 
DAC was preferred over IAC if even small or medium size in-
farcts were complicated by HTr. For IAC, the preferred method 
of administration was heparin bridging (68.2%), followed by 
warfarin alone (16.9%), and aspirin bridging (15.0%). Of those 
who practice acute AC, approximately 60% responded that they 
would commence treatment regardless of past history of sponta-
neous ICH or CMBs.
Factors related to IAC practice
Twenty two participants (10.7%) stated that they would initi-
ate IAC in all 7 cases, and 9 (4.4%) replied that they would not 
commence IAC in any cases. The remainder, the majority of 
participants, decided whether to initiate IAC on a case by case 
Ju-Hun Lee, et al. 
www.stroke.or.kr  123
basis (Figure 2). 
We analysed factors related to the IAC decision (Table 2). 
Those who reported stroke to be their specialty were less likely 
to initiate IAC than those who did not (56.4% vs. 64.3%, 
P=0.005).  IAC was less likely performed in cases with large 
infarcts and HTr (35.9% vs. 68.2%, P=0.001; 34.9% vs. 68.6%, 
P=0.001). Multivariable analysis revealed a statistically sig-
nifi cant relationship between stroke specialty, large infarct, and 
presence of HTr with the decision to initiate IAC (P=0.001, 
P<0.001, P<0.001). Although IAC was more often chosen in 
cases with cerebellar than supratentorial infarction (63.9% vs. 
57.0%), multivariable analysis did not show a statistically sig-
TABLE 1. Summary of participants’ anticoagulation treatment method for each case
Case no.
Case description Q1* Q2† Q1* Q3‡
Location and size of infarct HTr IAC? How? IAC? When? 
Case 1 Large supratentorial infarct (>1/2 of MCA) No
Yes
(35.6%)
H (71.2%)
No
(64.4%)
 ~1wk (27.3%)
A (11.0%)  1~2wk (53.0%)
W (17.8%)  2wk~ (19.7%) 
Case 2 Medium supratentorial infarct(1/2-1/3 of MCA) No
Yes
(86.3%)
H (71.8%)
No
(13.7%)
 ~1wk (57.1%)
A (14.1%)  1~2wk (39.3%)
W (14.1%)  2wk~ (3.6%) 
Case 3 Medium supratentorial infarct(1/2-1/3 of MCA) Yes
Yes
(24.4%)
H (66.0%)
No
(75.6%)
 ~1wk (12.9%)
A (12.0%)  1~2wk (45.2%)
W (22.0%)  2wk~ (41.9%) 
Case 4 Small supratentorial infarct (<1/3 of MCA) No
Yes
(93.2%)
H (66.5%)
No
(6.8%)
 ~1wk (85.7%)
A (16.2%)  1~2wk (0.0%)
W (17.3%)  2wk~ (14.3%) 
Case 5 Small supratentorial infarct (<1/3 of MCA) Yes
Yes
(45.4%)
H (57.0%)
No
(54.6%)
 ~1wk (27.7%)
A (22.6%)  1~2wk (38.4%)
W (20.4%)  2wk~ (33.9%) 
Case 6 Large cerebellar infarct (whole or near whole PICA) No
Yes
(36.1%)
H (71.6%)
No
(63.9%)
 ~1wk (24.4%)
A (12.2%)  1~2wk (46.6%)
W (16.2%)  2wk~ (29.0%) 
Case 7 Small cerebellar infarct No Yes(91.7%)
H (69.7%)
No
(8.3%)
 ~1wk (76.5%)
A (14.4%)  1~2wk (23.5%)
W (16.0%)  2wk~ (0.0%) 
Q: Do you commence AC in acute phase?
Case 8 Previous histroy of spontaneous ICH
 Usually, do not (35.8%)
 Usually, do (60.3%)
 Not applicable (3.9%)
Case 9 Multiple CMBs on GRE
 Usually, do not (36.8%)
 Usually, do (60.8%)
 Not applicable (2.4%)
* “Do you commence IAC?”, † “Which method of administration do you favor?”, ‡ “When do you start anticoagulation therapy?”.
HTr: hemorrhagic transformation of hemorrhagic infarct type, IAC: immediate anticoagulation therapy, MCA: middle cerebral 
artery, PICA: posterior infererior cerebellar artery, H: heparin bridging, A: aspirin bridging, W: warfarin alone, AC: anticoagulation 
therapy, Q: question, ICH: intracerebral hemorrhage, CMBs: cerebral microbleeds, GRE: gradient echo image.
FIGURE 2. The minority of participants stated that they would 
initiate immediate anticoagulation therapy (IAC) in all 7 cases (25 
participants, 10.7%) or not in any cases (9 participants, 4.4%). 
However, most participants decided whether to initiate IAC on a 
case by case basis. 
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nifi cant difference (P=0.593). No statistically signifi cant correla-
tions were seen between other variables and IAC.
We analysed factors related to the method of administration 
if IAC was initiated (Table 3). Participants who reported stroke 
to be their specialty tended to prefer aspirin bridging more than 
those who did not (P=0.035). Participants working in hospitals 
with ≥31 monthly acute stroke admissions also preferred aspirin 
bridging (P=0.001). No statistically signifi cant correlations were 
seen between other variables and method of administration. 
When DAC was initiated, those who reported stroke to be 
their specialty mostly preferred to start AC within one week than 
those who did not (Table 4). A signifi cant correlation was also 
seen between large infarct and HTr with the decision when to 
commence AC.
TABLE 2. Factors related to the decision to commence immediate anticoagulation therapy
Variables IAC (-)n (%) 
IAC (+)
n (%) 
Univariate Multivariate
P value P value 
Age (of the participant)
~42 293 (41.0) 421 (59.0) 
0.995 0.789
43~ 296 (41.1) 425 (58.9) 
Stroke specialty
No 165 (35.7) 297 (64.3) 
0.005 0.001
Yes 424 (43.6) 549 (56.4) 
Number of acute stroke 
patients per month
~30 216 (41.7) 302 (58.3) 
0.705 0.271
31~ 373 (40.7) 544 (59.3) 
Stroke unit
Absent 284 (39.4) 437 (60.6) 
0.2 0.11
Present 305 (42.7) 409 (57.3) 
Large infarct
No 326 (31.8) 699 (68.2) 
<0.001 <0.001 
Yes 263 (64.1) 147 (35.9) 
HTr
No 322 (31.4) 703 (68.6) 
<0.001 <0.001
Yes 267 (65.1) 143 (34.9) 
Location of infarct
Supratentorium 441 (43.0) 584 (57.0) 
0.016 0.593
Cerebellum 148 (36.1) 262 (63.9) 
Total 1435 589 (41.0) 846 (59.0) 
IAC: immediate anticoagulation therapy, HTr: hemorrhagic transformation of hemorrhagic infarct type.
TABLE 3. Factors related to the method of anticoagulation administration
Variables H. bridgingn (%)
A. bridging
n (%)
Warfarin alone
n (%) P value
Age (of the participant)
~42  297 (70.7)  53 (12.6)  71 (16.9) 
0.144
43~  281 (65.8)  74 (17.3)  72 (16.9) 
Stroke specialty
No  208 (69.6)  33 (11.0)  58 (19.4) 
0.035
Yes  370 (67.4)  94 (17.1)  85 (15.5) 
Number of acute stroke 
patients per month
~30  228 (75.0)  29 (9.5)  47 (15.5) 
0.001
31~  350 (64.3)  98 (18.0)  96 (17.6) 
Stroke unit
Absent  311 (71.2)  61 (14.0)  65 (14.9) 
0.140 
Present  267 (65.0)  66 (16.1)  78 (19.0) 
Large infarct
No  473 (67.5)  110 (15.7)  118 (16.8) 
0.435
Yes  105 (71.4)  17 (11.6)  25 (17.0) 
HTr
No  490 (69.7)  100 (14.2)  113 (16.1) 
0.105
Yes  88 (60.7)  27 (18.6)  30 (20.7) 
Location of infarct
Supratentorium  394 (67.2)  91 (15.5)  101 (17.2) 
0.677
Cerebellum  184 (70.2)  36 (13.7)  42 (16.0) 
Total 848  578 (68.2)  127 (15.0)  143 (16.9)  
H: heparin, A: aspirin, HTr: hemorrhagic transformation of hemorrhagic infarct type.
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We analysed factors related to acute AC practice in cases with 
a past history of spontaneous ICH, or with CMBs on GRE (Table 
5). In these cases, participants who reported stroke to be their 
specialty perform AC therapy less often (P=0.011, P=0.028). 
No statistically signifi cant correlations were seen between other 
variables and acute AC in these cases.
Discussion
In this study, we found that staff faculties (including instructors 
and professors) of Korean training hospitals selectively initiate 
IAC according to infarct size and the presence of HTr on initial 
imaging. Notably, if the cerebral infarction was not large in size 
and not complicated by HTr, nearly 90% of respondents stated 
they would initiate IAC. When performing IAC, the preferred 
method of administration was heparin bridging. When IAC was 
not commenced, the preferred option was to start AC between 
1-2 weeks after onset, although this varied with the size of infarct 
and the presence of HTr. In acute phase AC, most responded 
they would give AC regardless of a history of spontaneous ICH, 
or CMBs on GRE.
There have been few studies on AC in ACES. The Interna-
TABLE 4. Factors related to commencement time of anticoagulation therapy in cases of delayed anticoagulation
Variables ~1 wkn (%)
1~2 wk
n (%)
2 wk~
n (%) P value
Age (of the participant)
~42  66 (22.5)  149 (50.9)  78 (26.6) 
0.003
43~  94 (31.8)  110 (37.2)  92 (31.1) 
Stroke specialty
No  22 (13.3)  71 (43.0)  72 (43.6) 
<0.001  
Yes  138 (32.5)  188 (44.3)  98 (23.1) 
Number of acute stroke 
patients per month
~30  57 (26.4)  102 (47.2)  57 (26.4) 
0.445
31~  103 (27.6)  157 (42.1)  113 (30.3)
Stroke unit
Absent  81 (28.5)  119 (41.9)  84 (29.6) 
0.605
Present  79 (25.9)  140 (45.9)  86 (28.2) 
Large infarct
No  92 (28.2)  128 (39.3)  106 (32.5) 
0.025
Yes  68 (25.9)  131 (49.8)  64 (24.3) 
HTr
No  109 (33.9)  146 (45.3)  67 (20.8) 
<0.001 
Yes  51 (19.1)  113 (42.3)  103 (38.6) 
Location of infarct
Supratentorium  115 (26.1)  194 (44.0)  132 (29.9) 
0.482
Cerebellum  45 (30.4)  65 (43.9)  38 (25.7) 
Total 589  160 (27.2)  259 (44.0)  170 (28.9) 
HTr: hemorrhagic transformation of hemorrhagic infarct type.
TABLE 5. Factors related to the decision to commence anticoagulation therapy in acute cardioembolic infarct patients with previous 
spontaneous intracerebral hemorrhage (Case 8) or multiple cerebral microbleeds on gradient echo MR (Case 9)
Variables
Case 8: Do you commence AC in acute 
phase?
Case 9: Do you commence AC in acute 
phase?
Usually, 
do
n (%) 
Usually, 
do not
n (%) 
NA
n (%) P value
Usually, 
do
n (%) 
Usually, 
do not
n (%) 
NA
n (%) P value
Age (of the participant)
~42 61 (60.4) 38 (37.6) 2 (2.0) 
0.224
65 (64.4) 36 (35.6) 0 (0.0) 
0.042
43~ 62 (60.2) 34 (33.0) 7 (6.8) 59 (57.3) 38 (36.9) 6 (5.8) 
Stroke specialty
No 91 (65.5) 40 (28.8) 8 (5.8)
0.011
92 (66.2) 42 (30.2) 5 (3.6)
0.028
Yes 32 (49.2) 32 (49.2) 1 (1.5) 32 (49.2) 32 (49.2) 1 (1.5)
Number of acute stroke 
patients per month
~30 80 (61.1) 44 (33.6) 7 (5.3)
0.589
82 (62.6) 45 (34.4) 4 (3.1)
0.746
31~ 43 (58.9) 28 (38.4) 2 (2.7) 42 (57.5) 29 (39.7) 2 (2.7)
Stroke unit
Absent 59 (58.4) 35 (34.7) 7 (6.9)
0.221
62 (61.4) 35 (34.7) 4 (4.0)
0.649
Present 64 (62.1) 37 (35.9) 2 (1.9) 62 (60.2) 39 (37.9) 2 (1.9)
Total 204 123 (60.3) 72 (35.3) 9 (4.4) 124 (60.8) 74 (36.3) 6 (2.9) 
AC: anticoagulation therapy, NA: not applicable.
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tional Stroke Trial, comparing the effects of aspirin and subcuta-
neous unfractionated heparin initiated within 48 hours, revealed 
that the group treated with heparin had a lower recurrence rate of 
ischemic stroke within 2 weeks, although this effect was offset 
by an increased incidence of cerebral hemorrhage.6 However, it 
has been pointed out that this study has a number of limitations 
in that it was an open trial, with no clear defi nition for recurrent 
stroke, 50% of the heparin treated group were also taking 300 
mg aspirin, some patients received heparin before CT scanning, 
and patients with severe stroke were not excluded. The Heparin 
in Acute Embolic Stroke Trial, where LMWH and aspirin were 
compared in acute cerebral infarct patients with AF, did not 
demonstrate superior efficacy for LMWH over aspirin.5 This 
study excluded patients with a Scandinavian Stroke Scale score 
below 8. However, a treatment strategy based on infarct volume 
rather than neurologic severity score may be more reasonable.8 
Accordingly, even though these earlier studies claim no benefi ts 
for AC in ACES, this cannot be generalised due to the limita-
tions of these studies. Also, questions continue to be raised about 
the benefits of selective AC in ACES patients with a low risk 
of HTr, e.g. small infarcts. In this study, the fi nding that most of 
our participants prefer IAC for small to medium sized cerebral 
infarcts with no HTr can be interpreted as high expectations for 
the benefi ts of selective AC.
Oral administration of warfarin takes several days until an 
adequate anticoagulation effect is achieved. Early in the course 
of warfarin therapy, there may be net procoagulant effect due to 
a transient reduction in vitamin K-dependent coagulation inhibi-
tors.9 Heparin bridging is therefore recommended when starting 
oral warfarin, to achieve a rapid and effective anticoagulation ef-
fect.10 In this survey, most participants preferred heparin bridging 
when initiating IAC. However, a number of participants (30%) 
responded that they would not use heparin bridging, preferring 
aspirin bridging or warfarin alone. This can be interpreted as 
intent to slowly achieve an anticoagulation effect, reducing the 
possibility of HTr following ACES. 
When IAC is not initiated, many responded that they would 
commence AC between 1-2 weeks after onset. There is no clear 
evidence to support this practice. In the European Atrial Fibrilla-
tion Trial, where secondary preventative effects of anticoagulants 
were shown in cerebral infarct patients with AF, 46% of patients 
in the anticoagulant therapy group commenced treatment within 
2 weeks of onset.2 Even though this study does not give a clear 
rationale for commencing AC in ACES within 2 weeks, it does 
show that many clinicians consider it desirable to do so.
 There have been no studies of the effi cacy and safety of AC in 
acute stroke patients with a history of spontaneous ICH. Perhaps 
refl ecting the lack of evidence, many participants to this survey 
initiated AC in acute stroke despite a history of spontaneous 
ICH. However, we believe caution is required in administering 
acute AC in these patients. This is because, as demonstrated in 
our earlier study, a past history of spontaneous ICH increases the 
risk of HTr.8 CMBs on GRE, along with spontaneous ICH, also 
suggest a haemorrhagic tendency, and have been identified as 
risk factors for subsequent ICH after an ischemic stroke.11 How-
ever, there have been reports that CMBs, unlike spontaneous 
ICH, may not be related to HTr in acute cerebral infarction.8,12 
There is therefore no solid evidence as yet that CMBs are a 
contraindication for acute phase AC.
Analysis of factors related to AC practice revealed that stroke 
specialists were less likely to initiate IAC (56.4% versus 64.3%), 
and tended to prefer aspirin bridging (17.1% versus 11.3%), 
more than non-specialists. Also, when initiating DAC, stroke 
specialists were more likely to commence AC 2 or more weeks 
after onset (43.6% versus 31.1%), and tended to refrain from AC 
if there was a history of spontaneous ICH or CMBs were present 
(49.2% versus 28.8%, 49.2% versus 30.2%, respectively). This 
may be attributed to the tendency of stroke specialists to adhere 
to the current guidelines, which state that heparin is not effective 
in acute ischemic stroke, and aspirin is the gold standard. Despite 
these differences, stroke specialists nevertheless did initiate ag-
gressive AC in the acute phase using heparin.
There are several points in this survey that require attention. 
Firstly, one might think our results do not adequately reflect 
the opinion of all our subjects considering the response rate 
was 57.1%. However, as the majority of the reasons for non-
participants were either “not in charge of any stroke patients” or 
“not interested in the topic”, we can say that most staff mem-
bers directly involved in acute stroke treatment have participated 
in this survey. Secondly, the survey results are not necessarily 
identical to actual AC practice. Clinicians may choose more 
conservative treatments for the safety of their actual patients, as 
opposed to survey results based on hypothetical cases. Thirdly, 
we simplifi ed hypothetical cases according to the infarct loca-
tion, size, and HTr. We did not consider other factors related to 
AC practice, such as AC therapy for prevention of deep vein 
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thrombosis. We also simplifi ed antithrombotic therapy as hepa-
rin bridging, aspirin bridging, and warfarin alone. We did not 
consider the various regimens and titration schedules.
Despite the negative recommendations in the current guide-
lines, the high proportion of IAC therapy in acute cardioembolic 
stroke patients seen in this survey indicates that there are many 
questions to be answered in this area. In particular, many practi-
tioners selectively initiate IAC according to the presence of HTr 
and the size of the cerebral infarction, studies are further required 
into the effectiveness of selective IAC treatment in patients with 
a low risk of HTr.
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APPENDIX 1. The original questionnaire
(Case 1 – 7)
심방세동(atrial fi brillation)이 동반된 환자들의 diffusion-weighted image(DWI)와 gradient-echo sequence(GRE)입니다. 현재 발병 후 24
시간이 지난 시점이며, 항혈전제(항응고제 또는 항혈소판제) 치료의 다른 금기사항은 없습니다. 각각의 환자에서 선생님께서 주로 시행하는 항응고제 
치료 방법을 선택해 주십시오. 
1. 항응고제(anticoagulants: heparin or Warfarin) 투약을 바로 시작합니까? 
   ① 네 (→ 2번 질문으로 가십시오)
   ② 아니오 (→3번 질문으로 가십시오)
2. 항응고제(anticoagulants) 투약을 바로 시작한다면 방법은?
   ① Unfractionated heparin 또는 LMWH으로 시작하여 Warfarin으로 바꾼다.
   ② Aspirin을 비롯한 항혈소판제와 함께 Warfarin을 시작한다.
   ③ 항혈소판제 동반 투여 없이 Warfarin을 시작한다.
3. 항응고제(anticoagulants) 투약을 바로 시작하지 않는다면, 언제 시작을 고려합니까?
   ① 발병 후 1주일 이내
   ② 발병 후 1주일 -2주일
   ③ 발병 후 2주일 이후
(Case 8, 9)
심방세동(atrial fi brillation)이 동반된 뇌경색으로 발병 후 24시간이 지난 시점이라고 가정하고, 다음 질문에 답 하십시오.
1. 급성기에 항응고제(anticoagulants) 치료를 하게 되는 상황에서 과거에 뇌출혈의 병력을 고려합니까?
   ① 과거에 뇌출혈이 있는 경우에는 대개 항응고제(anticoagulants) 치료를 하지 않는다.
   ② 과거에 뇌출혈 여부와 상관없이 대개 항응고제(anticoagulants) 치료를 한다. 
   ③ 급성기에 전혀 항응고제(anticoagulants) 치료를 하지 않기 때문에 해당 없음.
2. 급성기에 항응고제(anticoagulants) 치료를 하게 되는 상황에서 GRE의 multiple cerebral microbleeds (CMBs) 여부를 고려합니까?
   ① Multiple CMBs가 있는 경우에는 대개 항응고제(anticoagulants) 치료를 하지 않는다.
   ② Multiple CMBs와 상관없이 대개 항응고제(anticoagulants) 치료를 한다.
   ③ 급성기에 전혀 항응고제(anticoagulants) 치료를 하지 않기 때문에 해당 없음.
